Revvity (RVTY) announced that its Revvity Signals Software business is launching Signals BioDesign, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining essential cloning methodologies with enterprise-grade collaboration.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity unveils Signals BioDesign offering
- Revvity price target lowered to $108 from $118 at Evercore ISI
- Revvity price target lowered to $96 from $105 at JPMorgan
- Revvity upgraded to Hold from Sell at Nephron Research
- Revvity’s AI Push Brings Innovation Potential but Heightened Operational, Legal, and Reputational Risks